Peripheral blood stem cell transplantation (PBSCT) is an effective treatment for hematological malignancies. Mobilization of peripheral blood progenitor cells performs in different ways among transplantation centers. Forceful mobilization schedules are comprised of growth factor alone, chemotherapy along with growth factor and also, a newly combination of novel agent such as plerixafor with any approach. With the appearance of numerous modifications in stem cell mobilization field over the past decade and advent of novel stem cell mobilization techniques, it seems to be necessary to review recent publications about stem cell mobilization strategies to respond above cited issues. Relevant literature was identified by a PubMed search of English-language literature using the terms mobilization, Allogeneic Stem Cells Transplantation, Autologous Stem Cells Transplantation and technical aspects of apheresis. Although many institutions have established their own procedures to improve stem cell mobilization success rates accompanying cost-effectiveness considerations, an optimal stem cell mobilization regimen and methods have not been well-defined, yet. Practical guidelines are required to address critical clinical issues including proper growth factor, the most Impressive chemotherapy and its dosage and appropriate time for leukapheresis initiation. Hence, based on literature, we prepared practical guidelines in this review.
INTRODUCTION
Hematopoietic Stem cells transplantation (HSCT) is become a curative option for patients who suffer from hematological malignancies. 1, 2 The usage of both autologous and allogeneic HSCT for adults and pediatric has exceedingly increased, over the past several decades. Small amounts of hematopoietic stem cells (HSCs) are able to circulate in Peripheral blood (PB).
3 So, HSCs mobilization from bone marrow (BM) to PB and their collection can be crucial element of HSCT programs. 4, 5 Despite the vast using of peripheral stem cells transplantation (PBSCT) as therapeutic strategy, it is difficult to achieve a consensus about its parameters. These parameters are type of growth factor and its optimal dosage, effectiveness type of chemotherapy and its dosage and how to predict poor mobilize patients and which time is best to initiate leukapheresis. 6 Nowadays, most transplantation institutions have adjusted own strategies according to their priorities and resource availabilities. Therefore, there are not any standard identical approaches. Hence, this paper aims to review current literature and guide lines on mobilization strategies to underscore the importance of mentioned problems.
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METHODS
Mobilization guidelines for autologous and allogeneic transplantation were obtained by the way of literature search. Extracted information about mobilization schedules, laboratory monitoring protocols and technical aspects of apheresis for adults and pediatrics are main foundations of presented guide lines in our review.
RESULTS

CSF dose recommendation for Allogeneic Transplantation in Adults
7-12 1-The recommended dose for sibling donors  5 µg/kg G-CSF twice per day as a split dose or 10 µg/kg/day as a single dose is advised.  Using higher split dose (12 µg/kg twice/day) results in higher collection yields with shorter collection time.
2-The recommended dose for unrelated donors
 G-CSF is administered for 4 or 5 consecutive days at a dose of 10 µg/kg daily.  During the PBSCs collection, the total processed blood volume (TPBV) does not be exceeding of 24 liters and it should be collected during 1 or 2 consecutive days.  Although persistent mobilization with G-CSF alone with doses of 10-16 µg/kg/day associated with higher incidence of failure rates in some patients or which thing is suboptimal but it may be an option owing to low toxicity and ease of scheduling. So that, this strategy will not suitable for patients with high risk of mobilization failure.  PB CD34‫‬ counts monitoring with preemptive plerixafor will lead to successful collection in the vast majority of patients.
Target Stem Cells dose for Allogeneic Transplantation in Adults
2) Chemotherapy plus growth factor mobilization strategies
29-32
G-CSF and chemotherapy dose elements  In this strategy, 5 to 10 µg/kg G-CSF as a single daily dose or pegfilgrastim (5 μg/kg/day) as a single administration can be used at the beginning of leukapheresis when peripheral blood CD34‫‬ cell counts or WBC count is adequate. In addition to, Lenograstim 150μg/m 2 /day (equivalent of 5 μg/kg/day subcutaneously) is advised to choose.  Cyclophosphamide (3-7 gr/m 2 ) or etoposide is commonly used for mobilization which results in higher collection yields during fewer days of apheresis than mobilization with growth factor alone. These benefits occur at the expense of increased hospitalizations for neutropenic fever, which occur in a substantial portion of patients. Current data do not declare that the concern which mobilization regimens include etoposide promote secondary malignancies. studies also suggest that etoposide-based mobilization approaches can be considered as alternative choice.
2B) Chemotherapy plus growth factor mobilization strategy in Lymphoma patients:
Chemotherapy + G-CSF as part of disease specific induction and salvage regimens have always regarded the preferred method. Such approaches can eliminate to require additional chemo-mobilizations or steady-state mobilizations before auto-HSCT in these heavily treated patients. Further, it is more effective than cyclophosphamide-based chemomobilization.
Optimal G-CSF Dose for Initial Mobilization in Pediatric Autologous Transplantation
33,34
 G-CSF (10 µg/kg/day or 12 µg/kg given twice per day) with leukapheresis beginning on the fifth day of G-CSF could result in successful mobilization in one day.
Target Stem Cells Dose for Autologous Transplantation in Adults and Pediatric
35-39
 2×10 6 CD34‫‬ cells/kg for single transplant has generally been accepted as a safe minimum count. Lower counts will concomitant the risk of delayed neutrophil and platelet engraftment.  5×10 6 CD34 cells/kg has been accepted as suitable optimal collected cells for successful transplantation.
Higher CD34‫‬ cell doses(>6×10 6 /kg) have been associated with faster hematopoietic recovery, more robust long-term platelet recovery, reduced blood transfusion requirements and beside improved overall survival. However, there was no significant difference at the time of platelet recovery to 20×10 9 /L.
Special Considerations for Obese Patients
40,41
 Either single daily dose (14 µg/kg/day) or split dose was suggested (2×7 µg/kg/day) for obese patients.  Patients with low weight should have characterized by hemoglobin at least level of 12 g/dL. Otherwise, it should be reached to mentioned level by RBC transfusion.  In children who weigh less than 20 kg, the apheresis machine should be primed with RBCs and/or human albumin to lower the extracorporeal volume.  In severe thrombocytopenia situation, platelet transfusion should be considered to achieve platelet count above 40×109/L in order to prevent bleeding complications. A summary of stem cells mobilization and apheresis strategies and target cells dose for autologous stem cells transplantation in pediatrics is shown in Figure  3 .
Monitoring Peripheral Blood CD34‫‬ cell Counts in Adults and Pediatrics Autologous Transplantation
45-50
1-Legitimate reasons to G-CSF alone strategy selection  CD34‫‬ cell counts peak in blood between the fourth to sixth days of therapy was observed. In this schedule, CD34‫‬ cells monitoring should begin on either day 4 or 5.
29,32,43-45
2-Plerixafor plus G-CSF mobilization strategy:
 CD34‫‬ cell counts were checked on days 4 and 5 of G-CSF administration.
3-Chemo mobilize strategy option  CD34‫‬ counts generally begin 8 to 10 days after chemotherapy administrations.
Golden Time to Leukapheresis Initiation
44,45,51
 In chemo-mobilization strategy, the start of leukapheresis is commonly determined by threshold of CD34‫‬ cell counts. There is no consensus on optimal threshold; therefore, institutional practice or institutional local 
Prediction of High Risk Patients for Stem Cell Mobilization Failure
51-57
Prediction of mobilization after chemotherapy 1-Proven poor mobilizes definition  If the patient received 10 μg/kg G-CSF alone or ⩾5 μg/kg G-CSF after chemotherapy but circulating CD34+ cells peak is remained <20/μL for up to 6 days after mobilization will defined as proven poor mobilisers  Furthermore, if the CD34 cells yield <2.0×10 6 /kg in⩽3 apheresis up to 20 days after chemomobilization regiment, it will define in this category. 
2-Predicted poor mobilisers
1-Prior to apheresis
11-19
 Borderline'‫‬ poor‫‬ mobilisers: CD34 cells/μL at maximum stimulation will detected in PB and it could be yielded 1.5-2×10 6 /kg CD34 cells after apheresis.  Relative'‫‬poor‫‬mobilisers: 6-10 CD34 cells/μL at maximum stimulation will detected in PB and it could be yielded <1×10 6 /kg CD34 cells after apheresis.  Absolute'‫‬ poor‫‬ mobilizers: ≤5 CD34 cells/μL at maximum stimulation will detected in PB and it could be yielded about 0.75×10 6 /kg CD34 cells after apheresis. 
2-After apheresis
Relatively Poor Mobilize and Poor Mobilize
 Preemptive use of plerixafor should be considered. A summary of apheresis and mobilization strategies based on CD34 cell count prior to apheresis for poor mobilize patients in autologous stem cells transplantation is shown in Figure 5 .  During G-CSF mobilization, significant increase in spleen size was observed. The median spleen volume increased by 1.47-folds on first day of leukapheresis but declined to near pretreatment size after 7 days of leukapheresis. In only 9% of patients splenic volumes increase into more than 2-folds.  There was no correlation between change in spleen volume, G-CSF dose, absolute neutrophil count peak, CD34‫‬ cells yield, or donor weight.  Despite the lack of documentations to support the association between hematological parameters and splenic enlargement or risk of splenic rupture, current data declared that G-CSF and Plerixafor administration should withhold when the WBC count exceeds 100 × 10 9 and exceeds 75×10 9 /L, respectively.
Threshold of Leukocytosis for Growth Factor Held
CONCLUSION
PBSC mobilization can be enhanced with a proper approach in allogeneic and autologous HSCT. In autologous HSCT, depended on the patient's disease and treatment protocol the results of stem cell collection will be different. A low CD34+ cell count in PB before apheresis is a key predictor 
